Advertisement

Unmet Needs in Psychiatry: Bipolar Depression

  • Ross J. BaldessariniEmail author
  • Leonardo Tondo
  • Gustavo H. Vázquez
Chapter
  • 43 Downloads

Abstract

Depressive phases of bipolar disorders (BD) present major challenges for treatment and comprehensive clinical management. They are the main component of psychiatric morbidity in BD, even with treatment, and are associated with excess morbidity and mortality from co-occurring general-medical disorders as well as very high suicide risk. BD patients exceed the general population in risks for a range of medical disorders, notably including metabolic syndrome marked by obesity and diabetes, as well as cardiovascular disorders including congestive heart failure and stroke. Some of these may have a selective relationship with bipolar depression as well as reflecting overall psychiatric morbidity. Resulting mortality rates are several-times higher than in the general population and some other psychiatric disorders. Suicide risk is approximately 20-times above general-population rates, greater than with most other major psychiatric disorders, and strongly associated with mixed (agitated-dysphoric) and depressive phases of BD. Specific, clinically effective prediction of individual suicidal behavior and its timing is very limited. Treatments that may reduce suicide risk, including lithium and perhaps clozapine or ketamine, are not securely proved effective or remain untested. Treatment of bipolar depression is far less well investigated than unipolar depression, and the value of antidepressants effective in short-term and prophylactic treatment of major depressive disorder remains controversial for bipolar depression and they are best avoided with current agitated-mixed dysphoric states. For bipolar depression, evidence of efficacy of mood-stabilizing agents, including lithium and several anticonvulsants (except lamotrigine, long-term) remains limited; emerging use of modern antipsychotics is encouraging for short-term treatment of acute bipolar depression, especially with mixed features. All available treatments used for bipolar depression present risks that include adverse metabolic and neurological effects.

Keywords

Bipolar disorder Depression Disability Morbidity Mortality Suicide 

Notes

Acknowledgments

Supported by a grant from the Bruce J Anderson Foundation and by the McLean Private Donors Psychiatry Research Fund (to RJB), and a grant from the Aretaeus Foundation of Rome (to LT).

Disclosures

No author or immediate family member has financial relationships with commercial organizations that might appear to represent potential conflicts of interest with the material presented.

References

  1. 1.
    Baldessarini RJ, Pérez J, Salvatore P, Trede K, Maggini C. History of bipolar manic-depressive disorder. In: Yildiz A, Nemeroff C, Ruiz P, editors. The bipolar book: history, neurobiology, and treatment. New York: Oxford University Press; 2015. p. 3–20, chap. 1.CrossRefGoogle Scholar
  2. 2.
    Salvatore P, Baldessarini RJ, Centorrino F, et al. Weygandt’s, the manic-depressive mixed states: a translation and commentary on its significance in the evolution of the concept of bipolar manic-depressive disorder. Harv Rev Psychiatry. 2002;10(5):255–75.PubMedCrossRefGoogle Scholar
  3. 3.
    Trede K, Salvatore P, Baethge C, Gerhard A, Maggini C, Baldessarini RJ. Manic-depressive illness: evolution in Kraepelin’s textbook, 1883–1926. Harv Rev Psychiatry. 2005;13(3):155–78.PubMedCrossRefGoogle Scholar
  4. 4.
    Cuellar AK, Johnson SL, Winters R. Distinctions between bipolar and unipolar depression. Clin Psychol Rev. 2005;25(3):307–39.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Akiskal HS. Emergence of the bipolar spectrum: validation along clinical-epidemiologic and familial-genetic lines. Psychopharmacol Bull. 2007;40(4):99–115.PubMedGoogle Scholar
  6. 6.
    Goodwin FK, Jamison KR. Manic-depressive illness. 2nd ed. New York: Oxford University Press; 2007.Google Scholar
  7. 7.
    Yildiz A, Nemeroff C, Ruiz P, editors. The bipolar book: history, neurobiology, and treatment. New York: Oxford University Press; 2015.Google Scholar
  8. 8.
    Rihmer Z, Akiskal KK, Rihmer A, Akiskal HS. Current research on affective temperaments. Curr Opin Psychiatry. 2010;23(1):12–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Baldessarini RJ, Vázquez G, Tondo L. Treatment of cyclothymic disorder. Psychother Psychosom. 2011;80(3):131–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Perugi G, Hantouche E, Vannucchi G. Diagnosis and treatment of cyclothymia: the “primacy” of temperament. Curr Neuropharmacol. 2017;15(3):372–9.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Tondo L, Vázquez GH, Pinna M, Vaccotto PA, Baldessarini RJ. Characteristics of depressive and bipolar patients with mixed features. Acta Psychiatr Scand. 2018;138(3):243–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden C. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010a;18(3):143–57.PubMedCrossRefGoogle Scholar
  13. 13.
    Ösby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Tondo L, Baldessarini RJ. Suicide in bipolar disorder. In: Yildiz A, Nemeroff C, Ruiz P, editors. The bipolar book: history, neurobiology, and treatment. New York: Oxford University Press; 2015. p. 509–28, chap. 37.CrossRefGoogle Scholar
  15. 15.
    Tondo L, Pompili M, Forte A, Baldessarini RJ. Suicide attempts in bipolar disorders: comprehensive review of 101 reports. Acta Psychiatr Scand. 2016;133(3):174–86.PubMedCrossRefGoogle Scholar
  16. 16.
    Vázquez GH, Holtzman J, Tondo L, Baldessarini RJ. Efficacy and tolerability of treatments for bipolar depression. J Affect Disord. 2015;183(9):258–62.PubMedCrossRefGoogle Scholar
  17. 17.
    Vázquez GH, Forte A, Camino S, Tondo L, Baldessarini RJ. Psychiatric comorbidity in bipolar disorder: treatment implications: anxiety syndromes and substance abuse. In: Carvalho E, Vieta E, editors. The treatment of bipolar disorder: integrative treatment strategies and future directions. New York: Oxford University Press; 2017. p. 225–54, chap. 17.Google Scholar
  18. 18.
    Ösby U, Westman J, Hällgren J, Gissler M. Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987–2010. Eur J Pub Health. 2018;26(5):867–71.CrossRefGoogle Scholar
  19. 19.
    Vázquez GH, Gonda X, Lolich M, Tondo L, Baldessarini RJ. Suicidal risk and affective temperaments evaluated with TEMPS-A. Harv Rev Psychiatry. 2018;26(1):8–18.PubMedCrossRefGoogle Scholar
  20. 20.
    Baethge C, Tondo L, Bratti IM, et al. Prophylaxis latency and outcome in bipolar disorders. Can J Psychiatr. 2003;48(7):449–57.CrossRefGoogle Scholar
  21. 21.
    Post RM, Leverich GS, Kupka RW, et al. Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry. 2010;71(7):864–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Vöhringer PA, Perlis RH. Discriminating between bipolar disorder and major depressive disorder. Psychiatr Clin N Am. 2016;39(1):1–10.CrossRefGoogle Scholar
  23. 23.
    Salvatore P, Baldessarini RJ, Tohen M, et al. McLean-Harvard international first-episode project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry. 2009;70(4):458–66.PubMedCrossRefGoogle Scholar
  24. 24.
    Salvatore P, Baldessarini RJ, Tohen M, et al. McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry. 2011;72(2):183–93.PubMedCrossRefGoogle Scholar
  25. 25.
    Bschor T, Angst J, Azorin JM, et al. Are bipolar disorders underdiagnosed in patients with depressive episodes? Results of the multicenter BRIDGE screening study in Germany. J Affect Disord. 2012;142(1–3):45–52.PubMedCrossRefGoogle Scholar
  26. 26.
    Kiejna A, Rymaszewska J, Hadrys T, Suvalska A, Lojko D, Rybakowski J. Bipolar or unipolar: the question for clinicians and researchers. J Affect Disord. 2006;93(1–3):177–83.PubMedCrossRefGoogle Scholar
  27. 27.
    Berk M, Dodd S, Callaly P, et al. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. J Affect Disord. 2007;103(1–3):181–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Stensland MD, Schultz JF, Frytak JR. Diagnosis of unipolar depression following initial identification of bipolar disorder: common and costly misdiagnosis. J Clin Psychiatry. 2008;69(5):749–58.PubMedCrossRefGoogle Scholar
  29. 29.
    Shen H, Zhang L, Xu C, Zhu J, Chen M, Fang Y. Analysis of misdiagnosis of bipolar disorder in an outpatient setting. Shanghai Arch Psychiatry. 2018;30(2):93–101.PubMedGoogle Scholar
  30. 30.
    Forte A, Baldessarini RJ, Tondo L, Vázquez G, Pompili M, Girardi P. Long-term morbidity in bipolar-I, bipolar-II, and major depressive disorders. J Affect Disord. 2015;178(6):71–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Perlis RH. Misdiagnosis of bipolar disorder. Am J Manag Care. 2005;11(Suppl 9):271–4.Google Scholar
  32. 32.
    Tondo L, Vázquez GH, Baldessarini RJ. Mania associated with antidepressant-treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010;121(6):404–14.PubMedCrossRefGoogle Scholar
  33. 33.
    Smith DJ, Griffiths E, Kelly M, Hood K, Craddock N, Simpson SA. Unrecognized bipolar disorder in primary care patients with depression. Br J Psychiatry. 2011;199(1):49–56.PubMedCrossRefGoogle Scholar
  34. 34.
    Newport DJ, Baldessarini RJ, Knight BT, et al. Comparison of women with confirmed versus presumably misdiagnosed bipolar disorder. J Clin Psychiatry. 2012;73(2):242–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Baldessarini RJ, Faedda GL, Offidani E, et al. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder. J Affect Disord. 2013;148(1):129–35.PubMedCrossRefGoogle Scholar
  36. 36.
    Barbuti M, Pacchiarotti I, Vieta E, et al. Antidepressant-induced hypomania/mania in patients with major depression: evidence from the BRIDGE-II-MIX study. J Affect Disord. 2017;219(9):187–92.PubMedCrossRefGoogle Scholar
  37. 37.
    Hantouche EG, Akiskal HS. Bipolar II vs. unipolar depression: psychopathologic differentiation by dimensional measures. J Affect Disord. 2005;84(2–3):127–32.PubMedCrossRefGoogle Scholar
  38. 38.
    Mendlowicz MV, Akiskal HS, Kelsoe JR, Rapaport MH, Jean-Louis G, Gillin JC. Temperament in the clinical differentiation of depressed bipolar and unipolar major depressive patients. J Affect Disord. 2005;84(2–3):219–23.PubMedCrossRefGoogle Scholar
  39. 39.
    Tondo L, Visioli C, Preti A, Baldessarini RJ. Bipolar disorders following initial depression: modeling predictive clinical factors. J Affect Disord. 2014;167(10):44–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Serra G, Koukopolos A, De Chiara L, et al. Features preceding diagnosis of bipolar versus major depressive disorders. J Affect Disord. 2015;173(3):134–42.PubMedCrossRefGoogle Scholar
  41. 41.
    Kupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007;9(5):531–325.PubMedCrossRefGoogle Scholar
  42. 42.
    De Dios C, Ezquiaga E, Garcia A, Soler B, Vieta E. Time spent with symptoms in a cohort of bipolar disorder outpatients in Spain: prospective, 18-month follow-up study. J Affect Disord. 2010;125(1–3):74–81.PubMedCrossRefGoogle Scholar
  43. 43.
    Brodaty H, Luscombe G, Peisah C, Anstey K, Andrews G. 25-year longitudinal, comparison study of the outcome of depression. Psychol Med. 2001;31(8):1347–59.PubMedCrossRefGoogle Scholar
  44. 44.
    Baldessarini RJ, Tondo L, Visioli C. First-episode types in bipolar disorder: predictive associations with later illness. Acta Psychiatr Scand. 2014;129(5):383–92.PubMedCrossRefGoogle Scholar
  45. 45.
    Uher R, Pallaskorpi S, Suominen K, Mantere O, Pavlova B, Isometsä E. Clinical course predicts long-term outcomes in bipolar disorder. Psychol Med. 2019;49(7):1109–17.PubMedCrossRefGoogle Scholar
  46. 46.
    Baldessarini RJ, Undurraga J, Vazquez GH, et al. Predominant recurrence polarity among 928 adult international bipolar I disorder patients. Acta Psychiatr Scand. 2012;125(4):293–302.PubMedCrossRefGoogle Scholar
  47. 47.
    Zimmerman M, Galione JN, Chelminski I, Young D, Dalrymple K, Ruggero CJ. Sustained unemployment in psychiatric outpatients with bipolar disorder: frequency and association with demographic variables and comorbid disorders. Bipolar Disord. 2010;12(7):720–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Arvilommi P, Suominen K, Mantere O, Valtonen H, Leppamaki S, Isometsa E. Predictors of long-term work disability among patients with type I and II bipolar disorder: prospective 18-month follow-up study. Bipolar Disord. 2015;17(8):821–35.PubMedCrossRefGoogle Scholar
  49. 49.
    Godard J, Baruch P, Grondin S, Lafleur MF. Psychosocial and neurocognitive functioning in unipolar and bipolar depression: 12 month prospective study. Psychiatry Res. 2012;196(1):145–53.PubMedCrossRefGoogle Scholar
  50. 50.
    Grande I, Goikolea JM, de Dios C, et al. Occupational disability in bipolar disorder: analysis of predictors of being on severe disablement benefit (PREBIS study data). Acta Psychiatr Scand. 2013;127(5):403–11.PubMedCrossRefGoogle Scholar
  51. 51.
    Wingo AP, Harvey PD, Baldessarini RJ. Cognitive impairment in euthymic bipolar disorder patients: functional implications. Bipolar Disord. 2009;11(2):113–25.PubMedCrossRefGoogle Scholar
  52. 52.
    Yoon JK, Kim SS, Choi SS, et al. Homicide and bipolar I disorder: 22-year study. Forensic Sci Int. 2012;217(1–3):113–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Baethge C, Baldessarini RJ, Khalsa HM, Hennen J, Salvatore P, Tohen M. Substance abuse in first-episode bipolar I disorder: indications for early intervention. Am J Psychiatry. 2005;162(5):1008–10.PubMedCrossRefGoogle Scholar
  54. 54.
    Baethge C, Hennen J, Khalsa HM, Salvatore P, Tohen M, Baldessarini RJ. Sequencing of substance abuse and affective morbidity in 166 first-episode bipolar I disorder patients. Bipolar Disord. 2008;10(6):738–41.PubMedCrossRefGoogle Scholar
  55. 55.
    Klimkiewicz A, Klimkiewicz J, Jokubczyk A, Kieres-Salomonski I, Wojnar M. Comorbidity of alcohol dependence with other psychiatric disorders: epidemiology of dual diagnosis. Psychiatr Pol. 2015;49(2):65–275.Google Scholar
  56. 56.
    Pavlova B, Perlis RH, Uher R. Lifetime prevalence of anxiety disorders in people with bipolar disorder: systematic review and meta-analysis. Lancet Psychiatry. 2015;2(8):710–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Preti A, Vrublevska J, Veroniki AA, Huedo-Medina TB, Fountoulakis KN. Prevalence, impact and treatment of generalized anxiety disorder in bipolar disorder: systematic review and meta-analysis. Evid Based Ment Health. 2016;19(3):73–81.PubMedCrossRefGoogle Scholar
  58. 58.
    Messer T, Lammers G, Müller-Siecheneder F, Schmidt RF, Latifi S. Substance abuse in patients with bipolar disorder: systematic review and meta-analysis. Psychiatry Res. 2017;253(7):338–50.PubMedCrossRefGoogle Scholar
  59. 59.
    Stokes PRA, Kalk NJ, Young AH. Bipolar disorder and addictions: the elephant in the room. Br J Psychiatry. 2017;211(3):132–4.PubMedCrossRefGoogle Scholar
  60. 60.
    Post RM, Leverich GS, McElroy S, et al. Prevalence of axis-II comorbidities in bipolar disorder: relationship to mood-state. Bipolar Disord. 2018;20(4):303–12.PubMedCrossRefGoogle Scholar
  61. 61.
    Hjorthøj AR, Madsen T, Agerbo E, Nordentoft M. Risk of suicide according to level of psychiatric treatment: nationwide nested case-control study. Soc Psychiatry Psychiatr Epidemiol. 2014;49(9):1357–65.PubMedCrossRefGoogle Scholar
  62. 62.
    Pinna M, Visioli C, Rago CM, Manchia M, Tondo L, Baldessarini RJ. Attention deficit-hyperactivity disorder in adult bipolar disorder patients. J Affect Disord. 2019;243(1):391–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale, meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–80.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Fornaro M, Solmi M, Veronese N, et al. Burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions. Int Rev Psychiatry. 2017;29(5):425–35.PubMedCrossRefGoogle Scholar
  65. 65.
    McIntyre RS, Soczynska JK, Beyer JL, et al. Medical comorbidity in bipolar disorder: reprioritizing unmet needs. Curr Opin Psychiatry. 2007;20(4):406–16.PubMedCrossRefGoogle Scholar
  66. 66.
    Almeida OP, McCaul K, Hankey GJ, et al. Duration of diabetes and its association with depression in later life: Health In Men Study (HIMS). Maturitas. 2016;86(4):3–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Almeida OP, Hankey GJ, Yeap BB, Golledge J, Flicker L. Older men with bipolar disorder: clinical associations with early and late illness. Int J Geriatr Psychiatry. 2018;33(12):1613–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Wu SI, Chen SC, Liu SI, et al. Relative risk of acute myocardial infarction in people with schizophrenia and bipolar disorder: population-based cohort study. PLoS One. 2015;10(8):e013463.Google Scholar
  69. 69.
    Tsai SY, Lee CH, Chen PH, et al. Risk factors for early cardiovascular mortality in patients with bipolar disorder. Psychiatry Clin Neurosci. 2017;71(10):716–24.PubMedCrossRefGoogle Scholar
  70. 70.
    Vancampfort D, Firth J, Schuch FB, et al. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder; global systematic review and meta-analysis. World Psychiatry. 2017;16(3):308–15.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Fiedorowicz JG, Prossin AR, Johnson CP, Christensen GE, Magnotta VA, Wemmie JA. Peripheral inflammation during abnormal mood states in bipolar I disorder. J Affect Disord. 2015;187(11):172–8.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Rosenblat JD, McIntyre RS. Bipolar disorder and inflammation. Psychiatr Clin N Am. 2016;39(1):125–37.CrossRefGoogle Scholar
  73. 73.
    Halaris A. Inflammation-associated co-morbidity between depression and cardiovascular disease. Curr Top Behav Neurosci. 2017;31(11):45–70.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Horsdal HT, Kohler-Forsberg O, Benros ME, Gasse C. C-reactive protein and white blood cell levels in schizophrenia, bipolar disorders and depression: associations with mortality and psychiatric outcomes, a population-based study. Eur Psychiatry. 2017;44(7):164–72.PubMedCrossRefGoogle Scholar
  75. 75.
    Vázquez GH, Camino S, Tondo L, Baldessarini RJ. Potential novel treatments for bipolar depression: ketamine, fatty acids, anti-inflammatory agents, and probiotics. CNS Neurol Disord Drug Targets. 2017;16(8):858–69.PubMedGoogle Scholar
  76. 76.
    Kalelioğlu T, Ünalan P, Kök B, et al. Atherogenic index of plasma as a cardiovascular risk marker in manic, depressive, and euthymic stages of bipolar disorder. Turk Kardiyol Dern Ars. 2018;46(1):32–8.PubMedGoogle Scholar
  77. 77.
    Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013;170(3):265–74.PubMedCrossRefGoogle Scholar
  78. 78.
    Pennix BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci. 2018;20(1):63–73.Google Scholar
  79. 79.
    American Heart Association (AHA). Symptoms and diagnosis of metabolic syndrome. http://www.heart.org/en/health-topics/metabolic-syndrome/symptoms-and-diagnosis-of-metabolic-syndrome. Accessed 18 Nov 2018.
  80. 80.
    Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of metabolic syndrome in the United States, 2003–2012. JAMA. 2015;313(19):1973–4.PubMedCrossRefGoogle Scholar
  81. 81.
    Silarova B, Giltay EJ, Van Reedt-Dortland A, et al. Metabolic syndrome in patients with bipolar disorder: comparison with major depressive disorder and nonpsychiatric controls. J Psychosom Res. 2015;78(4):391–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Moreira FP, Jansen K, Cardoso TA, et al. Metabolic syndrome in subjects with bipolar disorder and major depressive disorder in a current depressive episode: population-based study. J Psychiatr Res. 2017;92(9):119–23.PubMedCrossRefGoogle Scholar
  83. 83.
    Guha P, Bhowmick K, Mazumder P, Ghosal M, Chakraborty I, Burman P. Assessment of insulin resistance and metabolic syndrome in drug-naïve patients of bipolar disorder. Indian J Clin Biochem. 2014;29(1):51–6.PubMedCrossRefGoogle Scholar
  84. 84.
    Strassnig M, Kotov R, Cornaccio D, Fochtmann L, Harvey PD, Bromet EJ. Twenty-year progression of body-mass index in a county-wide cohort of people with schizophrenia or bipolar disorder identified at their first episode of psychosis. Bipolar Disord. 2017;19(5):336–43.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression, or bipolar disorder. World Psychiatry. 2015;14(20):119–36.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Høye A, Nesvåg R, Reichborn-Kiennerud T, Kacobsen BK. Sex differences in mortality among patients admitted with affective disorders in North Norway: 33-year prospective register study. Bipolar Disord. 2016;18(3):272–81.PubMedCrossRefGoogle Scholar
  87. 87.
    Hällgren J, Ösby U, Westman J, Gissler M. Mortality trends in external causes of death in people with mental health disorders in Sweden, 1987-2010. Scand J Public Health. 2018;47(2):121–6.PubMedCrossRefGoogle Scholar
  88. 88.
    Hayes JF, Marston L, Walters K, King MB, Osborn PJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. Br J Psychiatry. 2017;211(3):175–81.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Staudt-Hansen P, Frahm-Laursen M, Grøntved S, Puggard-Vogt-Straszek S, Licht RW, Nielsen RE. Increasing mortality gap for patients diagnosed with bipolar disorder: nationwide study with 20 years of follow-up. Bipolar Disord. 2019;21(3):270–5.PubMedCrossRefGoogle Scholar
  90. 90.
    Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: meta-review. World Psychiatry. 2014;13(2):153–60.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Brietzke E, Mansur RB, McIntyre RS. Impact of inequalities in healthcare on the mortality risk of individuals with severe mental illnesses. Braz J Psychiatry. 2017;39(3):193–4.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Hjorthøj C, Drivsholm-Østergaard ML, Eriksen-Benros M, et al. Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: nationwide, prospective, register-based study. Lancet Psychiatry. 2015;2(9):801–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Dickerson F, Origoni A, Schroeder J, et al. Natural cause mortality in persons with serious mental illness. Acta Psychiatr Scand. 2018;137(5):371–9.PubMedCrossRefGoogle Scholar
  94. 94.
    World Health Organization (WHO). International suicide rates, 2018. http://www.who.int/gho/mental_health/suicide_rates_crude/en/. Accessed 3 Dec 2018.
  95. 95.
    Bachmann S. Epidemiology of suicide and the psychiatric perspective. Int J Environ Res Public Health. 2018;15(7):E1425–47.PubMedCrossRefGoogle Scholar
  96. 96.
    Baldessarini RJ, Hennen J. Genetics of suicide: overview. Harv Rev Psychiatry. 2004;12(1):1–13.PubMedGoogle Scholar
  97. 97.
    Charlier P, Malaurie J, Wasserman D, et al. EPA guidance on suicide treatment and prevention needs to be adjusted to fight the epidemics of suicide at the North Pole area and other autochthonous communities. Eur Psychiatry. 2017;41(3):129–31.PubMedCrossRefGoogle Scholar
  98. 98.
    Levey DF, Polimanti R, Cheng Z, et al. Genetic associations with suicide attempt severity and genetic overlap with major depression. Transl Psychiatry. 2019;9:22–4.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Tondo L, Albert M, Baldessarini RJ. Suicide rates in relation to health-care access in the United States. J Clin Psychiatry. 2006;67(4):517–23.PubMedCrossRefGoogle Scholar
  100. 100.
    Diekstra RFW. Epidemiology of suicide and parasuicide. Acta Psychiatr Scand Suppl. 1993;371(Suppl):9–20.PubMedCrossRefGoogle Scholar
  101. 101.
    Simon RI, Hales RE, editors. Textbook of suicide assessment and management. 2nd ed. Washington: American Psychiatric Press; 2012.Google Scholar
  102. 102.
    Baldessarini RJ, Tondo L, Strombom IM, et al. Analysis of ecological studies of relationships between antidepressant utilization and suicidal risk. Harv Rev Psychiatry. 2007;15(4):133–45.PubMedCrossRefGoogle Scholar
  103. 103.
    Nordstrom P, Samuelsson M, Åsberg M. Survival analysis of suicide risk after attempted suicide. Acta Psychiatr Scand. 1995;91(5):336–40.PubMedCrossRefGoogle Scholar
  104. 104.
    American Psychiatric Association (APA). Practice guideline for the assessment and treatment of patients with suicidal behaviors. Am J Psychiatry. 2003;160(11 Suppl):1–60.Google Scholar
  105. 105.
    Oquendo MA, Chaudhury SR, Mann JJ. Pharmacotherapy of suicidal behavior in bipolar disorder. Arch Suicide Res. 2005;9(3):237–50.PubMedCrossRefGoogle Scholar
  106. 106.
    Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: meta-analytic review. Bipolar Disord. 2006;8(5):625–39.PubMedCrossRefGoogle Scholar
  107. 107.
    Lenz B, Röther M, Bouna-Pyrrou P, Mühle C, Tektas OY, Kornhuber J. Androgen model of suicide completion. Prog Neurobiol. 2019;172(1):84–103.PubMedCrossRefGoogle Scholar
  108. 108.
    Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035–43.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Sheehan DV, Giddens JM. Suicidality: roadmap for assessment and treatment. Tampa: Harm Research Press; 2015.Google Scholar
  110. 110.
    Tondo L, Isacsson G, Baldessarini RJ. Suicide in bipolar disorder: risk and prevention. CNS Drugs. 2003;17(7):491–511.PubMedCrossRefGoogle Scholar
  111. 111.
    Kessler RC, Berglund P, Borges G, Nock M, Wang PS. Trends in suicide ideation, plans, gestures, and attempts in the US, 1990–1992 to 2001–2003. JAMA. 2005;293(20):2487–95.PubMedCrossRefGoogle Scholar
  112. 112.
    Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173(7):11–53.PubMedCrossRefGoogle Scholar
  113. 113.
    Goldsmith SK, Pellmar TC, Kleinman AM, Bunney WE Jr, editors. Reducing suicide. Washington: Institute of Medicine of the US National Academies of Science; 2002.Google Scholar
  114. 114.
    Plans L, Barrot C, Nieto E, et al. Association between completed suicide and bipolar disorder: systematic review. J Affect Disord. 2019;242(1):111–22.PubMedCrossRefGoogle Scholar
  115. 115.
    Tondo L, Lepri B, Baldessarini RJ. Suicidal status during antidepressant treatment in 789 Sardinian patients with major affective disorder. Acta Psychiatr Scand. 2008;118(2):106–15.PubMedCrossRefGoogle Scholar
  116. 116.
    Large M, Swaraj S. Suicide, substance use and natural causes are respectively the most important causes of mortality in the first year post discharge from psychiatric hospitals. Evid Based Ment Health. 2018;21(2):e8–9.PubMedCrossRefGoogle Scholar
  117. 117.
    Walter F, Carr MJ, Mok PLH, et al. Suicide methods and specific types of accidental death and fatal poisoning among discharged psychiatric patients: national cohort study. J Clin Psychiatry. 2018;79(6):17m11809–26.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Forte A, Buscaioni A, Fiorillo A, Pompili M, Baldessarini RJ. Suicidal risk following hospital discharge: review. Harv Rev Psychiatry. 2019;27(4):209–16.PubMedGoogle Scholar
  119. 119.
    Isometsä ET, Henriksson MM, Aro HM, Heikkinen ME, Kuoppasalmi KI, Lönnqvist JK. Suicide in major depression. Am J Psychiatry. 1994;151(4):530–6.PubMedCrossRefGoogle Scholar
  120. 120.
    Tondo L, Baldessarini RJ, Hennen J, et al. Suicide attempts in major affective disorder patients with comorbid substance use disorders. J Clin Psychiatry. 1999;60(2):63–9.PubMedGoogle Scholar
  121. 121.
    Tondo L, Lepri B, Baldessarini RJ. Risks of suicidal ideation, attempts and suicides among 2826 men and women with types I and II bipolar, and recurrent major depressive disorders. Acta Psychiatr Scand. 2007;116(6):419–28.PubMedCrossRefGoogle Scholar
  122. 122.
    Murphy SL, Xu J, Kochanek KD. Deaths: preliminary data for 2010. Nat Vital Stat Rep. 2012;60(4):1–51. http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_04.pdf. Accessed 20 Dec 2018.Google Scholar
  123. 123.
    Laughren TP. In Proceedings of a meeting of the Psychopharmacology Drug Advisory Committee (PDAC) concerning suicidal risk in trials of antidepressant drugs in juvenile and adult patients; 2006. http://www.fda.gov/ohrms/dockets/ac/06/briefing//2006-4272b1-01-fda.pdf. Accessed 22 Dec 2018.
  124. 124.
    Nock MK, Borges G, Bromet EJ, et al. Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. Br J Psychiatry. 2008;192(2):98–105.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Nock MK, Hwang I, Sampson N, et al. Cross-national analysis of associations among mental disorders and suicidal behavior: findings from WHO world mental health surveys. PLoS Med. 2009;6(8):e1000123–40.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Baldessarini RJ. Chemotherapy in psychiatry. 3rd ed. New York: Springer Press; 2013.CrossRefGoogle Scholar
  127. 127.
    Saunders KE, Hawton K. Clinical assessment and crisis intervention for the suicidal bipolar disorder patient. Bipolar Disord. 2013;15(5):575–83.PubMedCrossRefGoogle Scholar
  128. 128.
    Judd LL, Akiskal HS, Schettler PJ, et al. Long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530–7.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Baldessarini RJ, Salvatore P, Khalsa HM, et al. Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord. 2010b;12(3):264–70.PubMedCrossRefGoogle Scholar
  130. 130.
    Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82–91.CrossRefPubMedGoogle Scholar
  131. 131.
    Zalsman G, Hawton K, Wasserman D, et al. Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry. 2016;3(7):646–59.PubMedCrossRefGoogle Scholar
  132. 132.
    Isometsä ET. Suicide in bipolar I disorder in Finland: psychological autopsy findings from the National Suicide Prevention Project in Finland. Arch Suicide Res. 2005;9(3):251–60.PubMedCrossRefGoogle Scholar
  133. 133.
    Ernst CL, Bird SA, Goldberg JF, Ghaemi SN. Prescription of psychotropic medications for patients discharged from a psychiatric emergency service. J Clin Psychiatry. 2006;67(5):720–6.PubMedCrossRefGoogle Scholar
  134. 134.
    Ahmedani BK, Simon GE, Stewart C, et al. Healthcare contacts in the year before suicide death. J Gen Intern Med. 2014;29(6):870–7.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol. 2006;26(2):203–7.PubMedCrossRefGoogle Scholar
  136. 136.
    Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683–96.PubMedCrossRefGoogle Scholar
  137. 137.
    Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: systematic review of observational studies. CMAJ. 2009;180(3):291–7.PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Braun C, Bschor T, Franklin J, Baethge C. Suicides and suicide attempts during long-term treatment with antidepressants: meta-analysis of 29 placebo-controlled studies including 6934 patients with major depressive disorder. Psychother Psychosom. 2016;85(3):171–9.PubMedCrossRefGoogle Scholar
  139. 139.
    Möller HJ. Is there evidence for negative effects of antidepressants on suicidality in depressive patients? Systematic review. Eur Arch Psychiatry Clin Neurosci. 2006;256(8):476–96.PubMedCrossRefGoogle Scholar
  140. 140.
    Baldessarini RJ, Lau WK, Sim J, Sum MY, Sim K. Suicidal risks in reports of long-term treatment trials for major depressive disorder. Int J Neuropsychopharmacol. 2016;19(3):1–2.CrossRefGoogle Scholar
  141. 141.
    Koukopoulos A, Koukopoulos A. Agitated depression as a mixed state and the problem of melancholia. Psychiatr Clin N Am. 1999;22(3):547–64.CrossRefGoogle Scholar
  142. 142.
    Akiskal HS, Benazzi F, Perugi G, Rimher Z. Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord. 2005;85(3):245–58.PubMedCrossRefGoogle Scholar
  143. 143.
    Maj M, Pirozzi R, Magliano L, Fiorillo A, Bartoli L. Agitated “unipolar” major depression: prevalence, phenomenology and outcome. J Clin Psychiatry. 2006;67(5):712–9.PubMedCrossRefGoogle Scholar
  144. 144.
    Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. International Society for Bipolar Disorders (ISBD) Task-Force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249–62.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Beasley CM Jr, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: meta-analysis of controlled trials of treatment for depression. BMJ. 1991;303(3804):685–92.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Tollefson GD, Rampey AH Jr, Beasley CM Jr, Enas GG, Potvin JH. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol. 1994;14(3):163–9.PubMedCrossRefGoogle Scholar
  147. 147.
    Acharya N, Rosen AS, Polzer JP, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol. 2006;26(6):587–94.PubMedCrossRefGoogle Scholar
  148. 148.
    Plöderl M, Hengartner MP. Antidepressant prescription rates and suicide attempt rates from 2004 and 2016 in a nationally representative sample of adolescents in the USA. Epidemiol Psychiatr Sci. 2019;28:589.PubMedCrossRefGoogle Scholar
  149. 149.
    Khan A, Leventhal RM, Khan S, Brown WA. Suicide risk in patients with anxiety disorders: meta-analysis of the FDA database. J Affect Disord. 2002;68(2–3):183–90.PubMedCrossRefGoogle Scholar
  150. 150.
    Diefenbach GJ, Woolley SB, Goethe JW. Association between self-reported anxiety symptoms and suicidality. J Nerv Ment Dis. 2009;197(2):92–7.PubMedCrossRefGoogle Scholar
  151. 151.
    Gaertner I, Gilot C, Heidrich P, Gaertner HJ. Case control study on psychopharmacotherapy before suicide committed by 61 psychiatric inpatients. Pharmacopsychiatry. 2002;35(2):37–43.PubMedCrossRefGoogle Scholar
  152. 152.
    Yerevanian BI, Choi YM. Impact of psychotropic drugs on suicide and suicidal behaviors. Bipolar Disord. 2013;315(5):594–621.CrossRefGoogle Scholar
  153. 153.
    Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years’ follow-up. Arch Suicide Res. 2005;9(3):279–300.Google Scholar
  154. 154.
    Müller-Oerlinghausen B, Ahrens B, Felber W. Suicide-preventive and mortality-reducing effect of lithium. In: Bauer M, Grof P, Müller-Oerlinghausen B, editors. Lithium in neuropsychiatry. London: Informa Healthcare; 2006. p. 79–192.Google Scholar
  155. 155.
    Baldessarini RJ, Tondo L. Lithium and suicidal risk. Bipolar Disord. 2008;10(1):114–5.PubMedCrossRefGoogle Scholar
  156. 156.
    Roberts E, Cipriani A, Geddes JR, Nierenberg AA, Young AH. Evidence for lithium in suicide prevention. Br J Psychiatry. 2017;211(6):396–7.PubMedCrossRefGoogle Scholar
  157. 157.
    Felber W, Bauer M, Lewitzka U, Müller-Oerlinghausen B. Lithium clinics in Berlin and Dresden: 50-year experience. Pharmacopsychiatry. 2018;51(5):166–71.PubMedCrossRefGoogle Scholar
  158. 158.
    Malhi GS. Lithium: global perspective. Pharmacopsychiatry. 2018;51(5):220–1.PubMedCrossRefGoogle Scholar
  159. 159.
    Tondo L, Baldessarini RJ. Antisuicidal effects in mood disorders: are they unique to lithium? Pharmacopsychiatry. 2018;51(5):177–88.PubMedCrossRefGoogle Scholar
  160. 160.
    Marangell LB, Dennehy EB, Wisniewski SR, et al. Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder. J Clin Psychiatry. 2008;69(6):916–22.PubMedCrossRefGoogle Scholar
  161. 161.
    Oquendo MA, Galfalvy HC, Currier D, et al. Treatment of suicide attempters with bipolar disorder: randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatry. 2011;168(10):1050–6.PubMedPubMedCentralCrossRefGoogle Scholar
  162. 162.
    Tondo L, Hennen J, Baldessarini RJ. Reduced suicide risk with long-term lithium treatment in major affective illness: meta-analysis. Acta Psychiatr Scand. 2001;104(3):163–72.PubMedCrossRefGoogle Scholar
  163. 163.
    Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: systematic review of randomized trials. Am J Psychiatry. 2005;162(10):1805–19.PubMedCrossRefGoogle Scholar
  164. 164.
    Lauterbach E, Felber W, Müller-Oerlinghausen B, et al. Adjunctive lithium treatment in the prevention of suicidal behavior in depressive disorders: randomized, placebo-controlled, one-year trial. Acta Psychiatr Scand. 2008;118(6):469–79.PubMedCrossRefGoogle Scholar
  165. 165.
    Khan A, Khan SR, Hobus J, et al. Differential pattern of response in mood symptoms and suicide risk measures in severely ill depressed patients assigned to citalopram with placebo or citalopram combined with lithium: role of lithium levels. J Psychiatr Res. 2011;45(11):1489–96.PubMedCrossRefGoogle Scholar
  166. 166.
    Tondo L, Baldessarini RJ, Hennen J, Floris G, Silvetti F, Tohen M. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry. 1998;59(8):405–14.PubMedCrossRefGoogle Scholar
  167. 167.
    Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry. 2007;68(3):380–3.PubMedCrossRefGoogle Scholar
  168. 168.
    Wasserman D, Rihmer Z, Rujescu D, et al. European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur Psychiatry. 2012;27(2):129–41.PubMedCrossRefGoogle Scholar
  169. 169.
    Lewitzka U, Bauer M, Felber W, Müller-Oerlinghausen B. Antisuicidal effect of lithium: current state of research and its clinical implications for the long-term treatment of affective disorders. Nervenarzt. 2013;84(3):294–306.PubMedCrossRefGoogle Scholar
  170. 170.
    Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.PubMedPubMedCentralCrossRefGoogle Scholar
  171. 171.
    Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des. 2006;12(23):2985–92.PubMedCrossRefGoogle Scholar
  172. 172.
    Kovacsics CE, Gottesman II, Gould T. Lithium’s antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol. 2009;49(12):175–98.PubMedCrossRefGoogle Scholar
  173. 173.
    Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: mini-review. Neuropsychobiology. 2010;62(1):43–9.PubMedCrossRefGoogle Scholar
  174. 174.
    Manchia M, Hajek T, O’Donovan C, et al. Genetic risk of suicidal behavior in bipolar spectrum disorder: analysis of 737 pedigrees. Bipolar Disord. 2013;15(5):496–506.Google Scholar
  175. 175.
    Nelson JC, Spyker DA. Morbidity and mortality associated with medications used in the treatment of depression: analysis of cases reported to US poison control centers, 2000–2014. Am J Psychiatry. 2017;174(5):438–50.PubMedCrossRefGoogle Scholar
  176. 176.
    Tondo L, Baldessarini RJ. Reduction of suicidal behavior in bipolar disorder patients during long-term treatment with lithium. In: Koslow SH, Ruiz P, Nemeroff CB, editors. Concise guide to understanding suicide: epidemiology pathophysiology and prevention. Cambridge: Cambridge University Press; 2014. p. 217–28.CrossRefGoogle Scholar
  177. 177.
    Søndergård L, Lopez AG, Andersen PK, Kessing LV. Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide. Bipolar Disord. 2008;10(1):87–94.PubMedCrossRefGoogle Scholar
  178. 178.
    Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: data from a randomized prospective trial. Pharmacopsychiatry. 1996;29(3):103–7.PubMedCrossRefGoogle Scholar
  179. 179.
    Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290(11):1467–73.PubMedCrossRefGoogle Scholar
  180. 180.
    Food and Drug Administration (US FDA). Antiepileptic drugs and suicidality 2008. Anticon. https://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm192556.pdf. Accessed 22 Dec 2018.
  181. 181.
    Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior: lithium, divalproex and carbamazepine. J Affect Disord. 2007;103(1–3):23–8.PubMedCrossRefGoogle Scholar
  182. 182.
    Gibbons RD, Hur K, Brown CH, Mann JJ. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry. 2009;66(12):1354–60.PubMedPubMedCentralCrossRefGoogle Scholar
  183. 183.
    Smith EG, Søndergård L, Lopez AG, Andersen PK, Kessing LV. Association between consistent purchase of anticonvulsants or lithium and suicide risk: longitudinal cohort study from Denmark, 1995–2001. J Affect Disord. 2009;117(3):162–7.PubMedCrossRefGoogle Scholar
  184. 184.
    Baldessarini RJ, Tondo L. Suicidal risks during treatment of bipolar disorder patients with lithium versus anticonvulsants. Pharmacopsychiatry. 2009;42(2):72–5.PubMedCrossRefGoogle Scholar
  185. 185.
    Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: analysis of the FDA database. Am J Psychiatry. 2001;158(9):1449–54.PubMedCrossRefGoogle Scholar
  186. 186.
    Schneider-Thoma J, Efthimiou O, Huhn M, et al. Second-generation antipsychotic drugs and short-term mortality: systematic review and meta-analysis of randomized placebo-controlled trials. Lancet Psychiatry. 2018;5(8):653–63.PubMedCrossRefGoogle Scholar
  187. 187.
    Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalization due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224–9.PubMedPubMedCentralCrossRefGoogle Scholar
  188. 188.
    Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: meta-analysis. Schizophr Res. 2005;73(2–3):139–45.PubMedCrossRefGoogle Scholar
  189. 189.
    Haukka J, Tiihonen J, Härkänen T, Lönnqvist J. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol Drug Saf. 2008;17(7):686–96.PubMedCrossRefGoogle Scholar
  190. 190.
    Pompili M, Baldessarini RJ, Forte A, et al. Do atypical antipsychotics have antisuicidal effects? A hypothesis-generating overview. Int J Mol Sci. 2016;17(10):E1700–13.PubMedCrossRefGoogle Scholar
  191. 191.
    Wimberley T, MacCabe JH, Laursen TM, et al. Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry. 2017;174(10):990–8.PubMedCrossRefGoogle Scholar
  192. 192.
    Vermeulen JM, van Rooihen G, van de Kerkhof MPJ, Sutterland AL, Correll CU, de Haan L. Clozapine and long-term mortality risk in patients with schizophrenia: systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophr Bull. 2019;45(2):315–29.PubMedCrossRefGoogle Scholar
  193. 193.
    Patchan KM, Richardson C, Vyas G, Kelly DL. Risk of suicide after clozapine discontinuation: cause for concern. Ann Clin Psychiatry. 2015;27(4):253–6.PubMedPubMedCentralGoogle Scholar
  194. 194.
    Li XB, Tang YL, Wang CY, de Leon J. Clozapine for treatment-resistant bipolar disorder: systematic review. Bipolar Disord. 2015;17(3):235–47.PubMedCrossRefGoogle Scholar
  195. 195.
    Arensman E, Townsend E, Hawton K, et al. Psychosocial and pharmacological treatment of patients following deliberate self-harm: methodological issues involved in evaluating effectiveness. Suicide Life Threat Behav. 2001;31(2):169–80.PubMedCrossRefGoogle Scholar
  196. 196.
    Hawton K, Arensman E, Townsend E, et al. Deliberate self-harm: systematic review of efficacy of psychosocial and pharmacological treatments in preventing repetition. BMJ. 1998;317(7156):441–7.PubMedPubMedCentralCrossRefGoogle Scholar
  197. 197.
    Brown GK, Ten Have T, Henriques GR, Xie SX, Hollander JE, Beck AT. Cognitive therapy for the prevention of suicide attempts: randomized controlled trial. JAMA. 2005;294(5):563–70.PubMedCrossRefGoogle Scholar
  198. 198.
    Witt K, de Moraes DP, Salisbury TT, et al. Treatment as usual (TAU) as a control condition in trials of cognitive behavioral-based psychotherapy for self-harm: impact of content and quality on outcomes in a systematic review. J Affect Disord. 2018;235(8):434–47.PubMedCrossRefGoogle Scholar
  199. 199.
    Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry. 1991;48(12):1060–4.PubMedCrossRefGoogle Scholar
  200. 200.
    Chesin M, Stanley B. Risk assessment and psychosocial interventions for suicidal patients. Bipolar Disord. 2013;15(5):584–93.PubMedCrossRefGoogle Scholar
  201. 201.
    Rucci P, Frank E, Kostelnik B, et al. Suicide attempts in patients with bipolar I disorder during acute and maintenance phases of intensive treatment with pharmacotherapy and adjunctive psychotherapy. Am J Psychiatry. 2002;159(7):1160–4.PubMedCrossRefGoogle Scholar
  202. 202.
    Guthrie E, Kapur NE, Mackway-Jones K, et al. Predictors of outcome following brief psychodynamic-interpersonal therapy for deliberate self-poisoning. Aust N Z J Psychiatry. 2003;37(5):532–6.PubMedCrossRefGoogle Scholar
  203. 203.
    Mehlum L, Dieserud G, Ekeberg Ø, et al. Prevention of suicide: psychotherapy, drug treatment and electroconvulsive treatment. Kunnskapssenteret report 24-2006. Oslo: Norwegian Knowledge Centre for the Health Services; 2006.Google Scholar
  204. 204.
    Möller HJ. Attempted suicide: efficacy of different aftercare strategies. Int Clin Psychopharmacol. 1992;6(6):58–69.PubMedCrossRefGoogle Scholar
  205. 205.
    Cuijpers P, de Beurs DP, van Spijker BA, Berking M, Andersson G, Kerkhof AJ. Effects of psychotherapy for adult depression on suicidality and hopelessness: systematic review and meta-analysis. J Affect Disord. 2013;144(3):183–90.PubMedCrossRefGoogle Scholar
  206. 206.
    Parsaik AK, Singh B, Khosh-Chashm D, Mascarenhas SS. Efficacy of ketamine in bipolar depression: systematic review and meta-analysis. J Psychiatr Pract. 2015;21(6):427–35.PubMedCrossRefGoogle Scholar
  207. 207.
    Wilkinson ST, Ballard ED, Bloch MH, et al. Effect of a single dose of intravenous ketamine on suicidal ideation: systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175(2):150–8.PubMedCrossRefGoogle Scholar
  208. 208.
    Fink M, Kellner CH, McCall WV. Role of ECT in suicide prevention. J ECT. 2014;30(1):5–9.PubMedCrossRefGoogle Scholar
  209. 209.
    Chung DT, Ryan CJ, Hadzi-Pavlovic D, Singh SP, Stanton C, Large MM. Suicide rates after discharge from psychiatric facilities. JAMA Psychiat. 2017;74(7):694–702.CrossRefGoogle Scholar
  210. 210.
    Baldessarini RJ, Tondo L, Vázquez GH. Pharmacological treatment of adult bipolar disorder. Mol Psychiatry. 2019;24(2):198–217.PubMedCrossRefGoogle Scholar
  211. 211.
    Vázquez GH, Tondo L, Undurraga J, Baldessarini RJ. Overview of antidepressant treatment of bipolar depression. Int J Neuropsychopharmacol. 2013;16(7):1673–85.PubMedCrossRefGoogle Scholar
  212. 212.
    McGirr A, Vöhringer PA, Ghaemi SN, Lam RW, Yatham LN. Safety and efficacy of adjunctive second generation antidepressant therapy with a mood-stabilizer or an atypical antipsychotic in acute bipolar depression: systematic review and meta-analysis of randomized placebo-controlled trials. Lancet Psychiatry. 2016;3(12):1138–46.. [and eAppendix; accessible at doi.org/10.1016/S2215-0366(16)30264-4].PubMedCrossRefGoogle Scholar
  213. 213.
    Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495–553.PubMedPubMedCentralCrossRefGoogle Scholar
  214. 214.
    Baldessarini RJ, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv. 2008;59(10):1175–83.PubMedCrossRefGoogle Scholar
  215. 215.
    Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161(9):1537–47.PubMedCrossRefGoogle Scholar
  216. 216.
    Ghaemi SN, Wingo AF, Filkowski MA, Baldessarini RJ. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand. 2008;118(5):347–56.PubMedPubMedCentralCrossRefGoogle Scholar
  217. 217.
    Sidor MM, MacQueen GM. Update on antidepressant use in bipolar depression. Curr Psychiatry Rep. 2012;14(6):696–704.PubMedCrossRefGoogle Scholar
  218. 218.
    Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine vs. lithium monotherapy of bipolar II disorder: randomized, double-blind, placebo-substitution study. Am J Psychiatry. 2010;167(7):792–800.PubMedPubMedCentralCrossRefGoogle Scholar
  219. 219.
    McElroy SL, Weisler RH, Chan W, et al. Double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163–74.PubMedCrossRefGoogle Scholar
  220. 220.
    Altshuler LL, Sugar CA, McElroy SL, et al. Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: randomized, double-blind comparison. Am J Psychiatry. 2017;174(3):266–76.PubMedCrossRefGoogle Scholar
  221. 221.
    Fountoulakis KN, Vieta E, Young A, et al. Unmet needs in the treatment of bipolar disorder and recommendations for future research. Int J Neuropsychopharmacol. 2017;20(2):196–205.PubMedGoogle Scholar
  222. 222.
    Liu B, Zhang Y, Fang H, et al. Efficacy and safety of long-term antidepressant treatment for bipolar disorders: meta-analysis of randomized controlled trials. J Affect Disord. 2017;223(12):41–8.PubMedCrossRefGoogle Scholar
  223. 223.
    Gitlin MJ. Antidepressants in bipolar depression: an enduring controversy. Int J Bipolar Disord. 2018;6(1):25–31.PubMedPubMedCentralCrossRefGoogle Scholar
  224. 224.
    Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158:906–12.PubMedCrossRefGoogle Scholar
  225. 225.
    Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079–88.PubMedCrossRefGoogle Scholar
  226. 226.
    Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry. 2004;65:1715–9.PubMedCrossRefGoogle Scholar
  227. 227.
    Agosti V, Stewart JW. Hypomania with and without dysphoria: comparison of comorbidity and clinical characteristics of respondents from a national community sample. J Affect Disord. 2008;108(1–2):177–82.PubMedCrossRefGoogle Scholar
  228. 228.
    Ghaemi SN. Antidepressants in bipolar depression: an update. In Proceedings of the 168th annual meeting of the American Psychiatric Association; Toronto, Ontario, Canada; 16–20 May 2015.Google Scholar
  229. 229.
    Yatham LN, Vieta E, Goodwin GM, et al. Agomelatine or placebo as adjunctive therapy to a mood-stabilizer in bipolar I depression: randomized double-blind placebo-controlled trial. Br J Psychiatry. 2016;208(1):78–86.PubMedCrossRefGoogle Scholar
  230. 230.
    Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711–22.PubMedCrossRefGoogle Scholar
  231. 231.
    Vázquez GH, Tondo L, Baldessarini RJ. Comparison of antidepressant responses in patients with bipolar vs. unipolar depression: meta-analytic review. Pharmacopsychiatry. 2011;44(1):21–6.PubMedGoogle Scholar
  232. 232.
    Tondo L, Baldessarini RJ, Vázquez GH, Lepri B, Visioli C. Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders. Acta Psychiatr Scand. 2013;127(5):355–64.PubMedCrossRefGoogle Scholar
  233. 233.
    Cohn JB, Collins G, Ashbrook E, Wernicke JF. Combination of fluoxetine, imipramine, and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol. 1989;4:313–22.PubMedCrossRefGoogle Scholar
  234. 234.
    Fountoulakis KN, Kasper S, Andreassen O, et al. Efficacy of pharmacotherapy in bipolar disorder: report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci. 2012;262(1):1–48.PubMedCrossRefGoogle Scholar
  235. 235.
    Undurraga J, Baldessarini RJ, Valenti M, et al. Bipolar depression: clinical correlates of receiving antidepressants. J Affect Disord. 2012;139(1):89–93.PubMedCrossRefGoogle Scholar
  236. 236.
    Koukopoulos A, Reginaldi D, Tondo L, Visioli C, Baldessarini RJ. Course sequences in bipolar disorder: depressions preceding or following manias or hypomanias. J Affect Disord. 2013;151(1):105–10.PubMedCrossRefGoogle Scholar
  237. 237.
    Bond DJ, Noronha MM, Kauer-Sant’Anna M, Lam RW, Yatham LN. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: systematic review and meta-analysis. J Clin Psychiatry. 2008;69(10):1589–601.Google Scholar
  238. 238.
    Viktorin A, Lichtenstein P, Thase ME, et al. Risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. 2014;171(10):1067–673.PubMedCrossRefGoogle Scholar
  239. 239.
    Grande I, De Arce R, Jimenez-Arrieto MA, et al. Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DERES). Int J Neuropsychopharmacol. 2013;16(3):513–23.PubMedCrossRefGoogle Scholar
  240. 240.
    Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):351–9.. [and eAppendix; accessible at doi.org/10.1016/S2215-0366(14)70314-1].PubMedCrossRefGoogle Scholar
  241. 241.
    Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium, and second-generation antipsychotics. Pharmacopsychiatry. 2014;47(2):43–52.PubMedCrossRefGoogle Scholar
  242. 242.
    Sim K, Lau KL, Sim J, Sum MY, Baldessarini RJ. Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. Int J Neuropsychopharmacol. 2015;19(2):1–13.Google Scholar
  243. 243.
    Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid vs. gradual discontinuation of antidepressants. Am J Psychiatry. 2010;167(8):934–41.PubMedCrossRefGoogle Scholar
  244. 244.
    Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006;163(2):232–329.PubMedCrossRefGoogle Scholar
  245. 245.
    Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry. 2010;71(4):372–80.PubMedCrossRefGoogle Scholar
  246. 246.
    Erol A, Winham SJ, McElrory SL, et al. Sex differences in the risk of rapid cycling and other indicators of adverse illness course in patients with bipolar I and II disorder. Bipolar Disord. 2015;17(6):670–6.PubMedCrossRefGoogle Scholar
  247. 247.
    Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672–82.PubMedCrossRefGoogle Scholar
  248. 248.
    Reinares M, Rosa AR, Franco C, et al. Systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. Int J Neuropsychopharmacol. 2013;16(2):485–96.PubMedCrossRefGoogle Scholar
  249. 249.
    Vázquez GH, Tondo L, Undurraga J, Zaratiegui R, Selle V, Baldessarini RJ. Pharmacological treatment of bipolar depression. Adv Psychiatr Treat. 2014;20(1):193–201.CrossRefGoogle Scholar
  250. 250.
    Muzina DJ, Gao K, Kemp DE, et al. Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2011;72(6):813–9.PubMedCrossRefGoogle Scholar
  251. 251.
    Solmi M, Veronese N, Zaninoto L, et al. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS Spectr. 2016;21(5):403–18.PubMedCrossRefGoogle Scholar
  252. 252.
    Frye MA, Ha K, Kanba S, et al. International consensus group on depression prevention in bipolar disorder. J Clin Psychiatry. 2011;72(10):1295–310.PubMedCrossRefGoogle Scholar
  253. 253.
    Young AH, McElroy SL, Bauer M, et al. Double-blind, placebo-controlled study (EMBOLDEN I) of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression. J Clin Psychiatry. 2010;71(2):150–62.PubMedCrossRefGoogle Scholar
  254. 254.
    Bschor T. Lithium in the treatment of major depressive disorder. Drugs. 2014;74(8):855–62.PubMedCrossRefGoogle Scholar
  255. 255.
    Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346(6):f3646–59.PubMedCrossRefGoogle Scholar
  256. 256.
    Song J, Sjolander A, Joas E, et al. Suicidal behavior during lithium and valproate treatment: a within-individual 8-year prospective study of 50,000 patients with bipolar disorder. Am J Psychiatry. 2017;174(8):795–802.PubMedCrossRefGoogle Scholar
  257. 257.
    Durgam S, Earley W, Lipschitz A, et al. Eight-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar-I depression. Am J Psychiatry. 2016;173(3):271–81.PubMedCrossRefGoogle Scholar
  258. 258.
    Brown EB, McElroy SL, Keck PE Jr, et al. Seven-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006;67(7):1025–33.PubMedCrossRefGoogle Scholar
  259. 259.
    Tamayo JM, Zarate CA Jr, Vieta E, Vázquez GH, Tohen M. Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: systematic review and meta-analysis. Int J Neuropsychopharmacol. 2010;13(6):813–32.PubMedPubMedCentralCrossRefGoogle Scholar
  260. 260.
    Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. In: Weiner WJ, Tolosa E, editors. Hyperkinetic movement disorders. In: Aminoff MJ, Boller F, Swaab DF (series editors). Handbook of clinical neurology. Edinburgh: Elsevier Press; 2010, pp. 601–16.Google Scholar
  261. 261.
    Carbon M, Hsieh C-H, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use, meta-analysis. J Clin Psychiatry. 2017;78(3):e264–78.PubMedCrossRefGoogle Scholar
  262. 262.
    Centorrino F, Masters GA, Talamo A, Baldessarini RJ, Öngür D. Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Hum Psychopharmacol. 2012;27(5):521–6.PubMedCrossRefGoogle Scholar
  263. 263.
    Lindström L, Lindström E, Nilsson M, Höistad M. Maintenance therapy with second generation antipsychotics for bipolar disorder – systematic review and meta-analysis. J Affect Disord. 2017;213(12):138–50.PubMedCrossRefGoogle Scholar
  264. 264.
    Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2018;  https://doi.org/10.1038/s41380-018-0256-5; [Epub ahead of print 3 Oct].
  265. 265.
    Aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139–45.CrossRefGoogle Scholar
  266. 266.
    Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, Ritter MJ, Schak KM, Sola CL, Hanson AJ, Frye MA. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013;27(5):444–50.PubMedCrossRefGoogle Scholar
  267. 267.
    Muller J, Pentyala S, Dilger J, Pentyala S. Ketamine enantiomers in rapid and sustained antidepressant effects. Ther Adv Psychopharmacol. 2016;6(3):185–92.PubMedPubMedCentralCrossRefGoogle Scholar
  268. 268.
    Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4.PubMedCrossRefGoogle Scholar
  269. 269.
    Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-dependent antidepressant actions of ketamine metabolites. Nature. 2016;533(7604):481–2.PubMedPubMedCentralCrossRefGoogle Scholar
  270. 270.
    Williams NR, Heifets BD, Blasey C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175(12):1205–15.PubMedPubMedCentralCrossRefGoogle Scholar
  271. 271.
    Van de Voort JL, Morgan RJ, Kung S, et al. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord. 2016;206(12):300–4.CrossRefGoogle Scholar
  272. 272.
    Dhir A. Investigational drugs for treating major depressive disorder. Expert Opin Investig Drugs. 2017;26(1):9–24.PubMedCrossRefGoogle Scholar
  273. 273.
    Garay RP, Zarate CA Jr, Charpeaud T, et al. Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother. 2017;17(6):593–609.PubMedPubMedCentralCrossRefGoogle Scholar
  274. 274.
    Bahji A, Hawken ER, Sepehry AA, Cabrera CA, Vázquez GH. ECT beyond unipolar major depression: systematic review and meta-analysis of electroconvulsive therapy in bipolar depression. Acta Psychiatr Scand. 2019;139(3):214–26.PubMedGoogle Scholar
  275. 275.
    Itagaki K, Takebayashi M, Shibasaki C, et al. Factors associated with relapse after a response to electroconvulsive therapy in unipolar versus bipolar depression. J Affect Disord. 2017;208(1):113–9.PubMedCrossRefGoogle Scholar
  276. 276.
    Perugi G, Medda P, Toni C, et al. Role of electroconvulsive therapy (ECT) in bipolar disorder: effectiveness in 522 patients with bipolar depression, mixed-state, mania and catatonic features. Curr Neuropharmacol. 2017;15(3):359–71.PubMedPubMedCentralCrossRefGoogle Scholar
  277. 277.
    Liang CS, Chung CH, Ho PS, Tsai CK, Chien WC. Superior antisuicidal effects of electroconvulsive therapy in unipolar disorder and bipolar depression. Bipolar Disord. 2018;41(3):341–53.Google Scholar
  278. 278.
    Tseng PT, Chen YW, Tu KY, et al. Light therapy in the treatment of patients with bipolar depression: meta-analytic study. Eur Neuropsychopharmacol. 2016;26(6):1037–47.PubMedCrossRefGoogle Scholar
  279. 279.
    Kurczewska E, Ferensztajn-Rochowiak E, Jasińska-Mikołajczyk A, Chłopocka-Woźniak M, Rybakowski JK. Augmentation of pharmacotherapy by sleep deprivation with sleep phase advance in treatment-resistant depression. Pharmacopsychiatry. 2019;52(4):186–92.PubMedCrossRefGoogle Scholar
  280. 280.
    Sit DK, McGowan J, Wiltrout C, et al. Adjunctive bright light therapy for bipolar depression: randomized double-blind placebo-controlled trial. Am J Psychiatry. 2018;175(2):131–9.PubMedCrossRefGoogle Scholar
  281. 281.
    Suzuki M, Dallaspezia S, Locatelli C, Uchiyama M, Colombo C, Benedetti F. Does early response predict subsequent remission in bipolar depression treated with repeated sleep deprivation combined with light therapy and lithium? J Affect Disord. 2018;229(3):371–6.PubMedCrossRefGoogle Scholar
  282. 282.
    Cimpianu CL, Strube W, Falkai P, Palm U, Hasan A. Vagus nerve stimulation in psychiatry: systematic review of the available evidence. J Neural Transm. 2017;124(1):145–58.PubMedCrossRefGoogle Scholar
  283. 283.
    Conway CR, Kumar A, Xiong W, Bunker M, Aaronson ST, Rush AJ. Chronic vagus nerve stimulation significantly improves quality of life in treatment-resistant major depression. J Clin Psychiatry. 2018;79(5):52–9.CrossRefGoogle Scholar
  284. 284.
    Salloum NC, Walker MC, Gangwani S, Conway CR. Emergence of mania in two middle-aged patients with a history of unipolar, treatment-refractory depression receiving vagus nerve stimulation. Bipolar Disord. 2017;19(1):60–4.PubMedCrossRefGoogle Scholar
  285. 285.
    Nierenberg AA, Alpert JE, Gardner-Schuster EE, Seay S, Mischoulon D. Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry. 2008;64(6):455–60.PubMedCrossRefGoogle Scholar
  286. 286.
    Mayberg HS. Targeted electrode-based modulation of neural circuits for depression. J Clin Invest. 2009;119(4):717–25.PubMedPubMedCentralCrossRefGoogle Scholar
  287. 287.
    Loo C, Katalinic N, Mitchell PB, Greenberg B. Physical treatments for bipolar disorder: review of electroconvulsive therapy, stereotactic surgery and other brain stimulation techniques. J Affect Disord. 2011;32(1–2):1–13.CrossRefGoogle Scholar
  288. 288.
    Filkowski MM, Mayberg HS, Holtzheimer PE. Considering eligibility for studies of deep brain stimulation for treatment-resistant depression: insights from a clinical trial in unipolar and bipolar depression. J ECT. 2016;32(2):122–6.PubMedPubMedCentralCrossRefGoogle Scholar
  289. 289.
    Oldani L, Altamura AC, Abdelghani M, Young AH. Brain stimulation treatments in bipolar disorder: review of the current literature. World J Biol Psychiatry. 2016;17(7):482–94.PubMedGoogle Scholar
  290. 290.
    Dondé C, Amad A, Nieto I, et al. Transcranial direct-current stimulation (tDCS) for bipolar depression: systematic review and meta-analysis. Prog Neuro-Psychopharmacol Biol Psychiatry. 2017;78(8):123–31.CrossRefGoogle Scholar
  291. 291.
    Widge AS, Malone DA Jr, Dougherty DD. Closing the loop on deep brain stimulation for treatment-resistant depression. Front Neurosci. 2018;12(3):1–9.Google Scholar
  292. 292.
    Fitzgerald PB, Hoy KE, Elliot D, McQueen S, Wambeek LE, Daskalakis ZJ. Negative double-blind controlled trial of sequential bilateral rTMS in the treatment of bipolar depression. J Affect Disord. 2016;198(7):158–62.PubMedCrossRefGoogle Scholar
  293. 293.
    Kazemi R, Rostami R, Khomami D, et al. Electrophysiological correlates of bilateral and unilateral repetitive transcranial magnetic stimulation in patients with bipolar depression. Psychiatry Res. 2015;240(6):364–75.Google Scholar
  294. 294.
    McMahon K, Herr NR, Zerubavel N, Hoertel N, Neacsiu AD. Psychotherapeutic treatment of bipolar depression. Psychiatr Clin N Am. 2016;39(1):35–56.CrossRefGoogle Scholar
  295. 295.
    Costa RT, Cheniaux E, Range BP, Versiani M, Nardi AE. Group cognitive behavior therapy for bipolar disorder can improve the quality of life. Braz J Med Biol Res. 2012;45:862–8.PubMedPubMedCentralCrossRefGoogle Scholar
  296. 296.
    Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: one-year randomized trial from the systematic treatment enhancement program. Arch Gen Psychiatry. 2007;64:419–26.PubMedPubMedCentralCrossRefGoogle Scholar
  297. 297.
    Bouwkamp CG, de Kruiff ME, van Troost TM, et al. Interpersonal and social rhythm group therapy for patients with bipolar disorder. Int J Group Psychother. 2013;63:97–115.PubMedCrossRefGoogle Scholar
  298. 298.
    Miklowitz DJ, George EL, Richards JA, Simoneau TL, Sudduth RL. Randomized study of family focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry. 2003;60:904–12.PubMedCrossRefGoogle Scholar
  299. 299.
    Lovas DA, Schuman-Olivier Z. Mindfulness-based cognitive therapy for bipolar disorder: systematic review. J Affect Disord. 2018;240:247–61.PubMedCrossRefGoogle Scholar
  300. 300.
    Deckersbach T, Hölzel B, Eisner L, Lazar SW, Nierenberg AA. Mindfulness-based cognitive therapy for bipolar disorder. New York: Guilford Press; 2014.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Ross J. Baldessarini
    • 1
    • 2
    Email author
  • Leonardo Tondo
    • 1
    • 2
    • 3
  • Gustavo H. Vázquez
    • 2
    • 4
  1. 1.Department of PsychiatryHarvard Medical SchoolBostonUSA
  2. 2.International Consortium for Bipolar & Psychotic Disorders Research, McLean HospitalBelmontUSA
  3. 3.Lucio Bini Mood Disorder CenterCagliariItaly
  4. 4.Department of PsychiatryQueen’s University School of MedicineKingstonCanada

Personalised recommendations